Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACC-001 + QS-21 Extension in Japanese AD Patients
NCT01238991Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Dec 2010
- Primary completion
- Dec 2013
- Modality
- Antibody Conjugates, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of vanutide cridificar in Alzheimer's disease (AD) (3 arms), sponsored by Pfizer. Primary endpoints: Number of Treatment Emergent Adverse Events (AEs) by Severity at 24 months, Number of Participants With Brain Abnormalities in Magnetic Resonance Imaging (MRI) Data at 24 months and 1 more. Started Dec 2010; status: terminated.
02
Drugs
vanutide cridificar
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01238991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01238991.